I should also note that our Management team’s limited time is heavily focused on Sofdra. As you can see in the performance rights and existing shares held, they are strongly aligned to sales of the product and will participate in upside.
Kaken have a broad portfolio of established products requiring attention. Profitability is regulated and compensation is less attractive.
BOT management also have something to prove to potential acquirers. Who is running the pen over Kaken?
I should also note that our Management team’s limited time is...
Add BOT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
31.0¢ |
Change
-0.005(1.59%) |
Mkt cap ! $577.0M | |||
| Open | High | Low | Value | Volume |
| 31.5¢ | 33.0¢ | 31.0¢ | $1.731M | 5.443M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 22 | 606129 | 31.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 31.5¢ | 92444 | 5 |
View Market Depth
| Last trade - 16.10pm 19/11/2024 (20 minute delay) ? |
| BOT (ASX) Chart |